Loading page
Loading page
Loading substance route
Redosing may produce dangerous cumulative effects. If affinity for opioid receptors exists, 3-HO-PCE may present unique risks relative to other dissociatives, particularly with repeated administration.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Chronic use has been characterized as moderately addictive with notable habit-forming properties. Compulsive redosing is commonly reported, particularly when smoked or vaporized due to the rapid onset and offset of effects. It has been described as more potentially habit-forming than ketamine, MXE, diphenidine, ephenidine, and DCK.
When addiction develops, cravings and withdrawal effects may occur upon cessation, though the specific nature and severity of physical withdrawal symptoms are not well characterized.
The exact toxic dosage is unknown. The toxicity and long-term health effects of recreational use have not been studied in any scientific context.
Repeated and excessive use over extended periods may cause bladder and urinary tract problems similar to those seen with ketamine, though potentially to a lesser extent due to the substance's higher potency requiring smaller amounts of material to be consumed.
Chronic use carries a moderate potential for psychosis and related adverse psychological effects. Mania is reportedly more common with this substance than with most other dissociatives. Delusions may also occur, particularly at higher doses or with repeated use.
Seizures may occur in predisposed individuals, particularly under physically taxing conditions such as dehydration, malnourishment, overheating, or fatigue. The extent to which this effect can be produced is not well characterized.
3-HO-PCE emerged on the grey market research chemical scene during the 2010s without any prior presence in scientific literature. Unlike its close structural analog 3-HO-PCP, which had been discussed in underground chemistry forums since the late 1990s before appearing as a designer drug in 2009,…
Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since July 18, 2019. Production, importation for market distribution, administration to others, and commercial distribution are criminal offenses. Personal possession is prohibited but does not carry criminal penalties.
Specifically listed as a controlled substance under Verzeichnis E of the Swiss narcotics scheduling system.
Controlled under the Misuse of Drugs Act 1971 via the arylcyclohexylamine generic clause introduced by Statutory Instrument 2013/239, effective February 26, 2013. This catch-all provision was recommended following an Advisory Council on the Misuse of Drugs report in October 2012 that addressed methoxetamine and its analogues. Possession, production, supply, and importation are criminal offenses.
Not scheduled as a controlled substance for research purposes. However, human consumption is prohibited under Swedish law.
Classified as a controlled drug under Turkish narcotics legislation. Possession, production, supply, and importation are all prohibited.
18 sources cited
